PSTX - Poseida Therapeutics, Inc.

QQQ $ 445.88 $ 1.10 (0.25 %)

DIA $ 395.58 $ 1.12 (0.28 %)

SPY $ 523.16 $ 2.25 (0.43 %)

TLT $ 90.86 $ 0.51 (0.56 %)

GLD $ 218.12 $ 1.83 (0.85 %)

Previous Close

$ 2.92

Open

$ 2.93

Bid

$ 2.92 x 400

Ask

$ 2.93 x 397

Day's Range

$ 2.86 - $ 2.95

52 Week Range

$ 1.54 - $ 4.27

Volume

484,048

Average Volume

Market Cap

280.38M

Beta (5Y Monthly)

$ 1.04

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-14-2024	03-31-2024	10-Q
2	03-07-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	03-09-2023	12-31-2022	10-K
7	11-10-2022	09-30-2022	10-Q
8	08-11-2022	06-30-2022	10-Q
9	05-12-2022	03-31-2022	10-Q
10	03-10-2022	12-31-2021	10-K
11	11-09-2021	09-30-2021	10-Q
12	08-12-2021	06-30-2021	10-Q
13	05-11-2021	03-31-2021	10-Q
14	03-11-2021	12-31-2020	10-K
15	11-12-2020	09-30-2020	10-Q
16	08-20-2020	06-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Poseida Therapeutics Q1 2024 Adj EPS $(0.2...
05/14/2024 20:26:40

Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of ...

Poseida Highlights Progress On Its Genetic...
05/09/2024 13:35:12

Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic rang...

HC Wainwright & Co. Reiterates Buy on Pose...
05/02/2024 17:36:00

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

Reported Earlier, Astellas And Poseida The...
05/02/2024 07:29:44

- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid ...

Astellas And Poseida Therapeutics Enter In...
05/01/2024 13:15:40

- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid ...

HC Wainwright & Co. Reiterates Buy on Pose...
04/22/2024 10:40:40

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

12-health-care-stocks-moving-in-tuesdays-pre-market-session

12 Health Care Stocks Moving In Tuesday's ...
04/16/2024 12:07:06

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
04/15/2024 20:31:28

Poseida Therapeutics Presents New Phase 1 ...
04/08/2024 16:01:30

Promising early data suggest patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therap...

Poseida Therapeutics Says FDA Granted Orph...
03/13/2024 20:08:14

why-mesoblast-shares-are-trading-higher-by-13-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Mesoblast Shares Are Trading Higher By...
03/11/2024 17:41:28

Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an ...

12-health-care-stocks-moving-in-mondays-intraday-session

12 Health Care Stocks Moving In Monday's I...
03/11/2024 17:31:12

eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday

EQT, Genie Energy And Other Big Stocks Mov...
03/11/2024 14:37:32

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

Poseida Therapeutics shares are trading lo...
03/08/2024 15:19:34

HC Wainwright & Co. Reiterates Buy on Pose...
03/08/2024 11:10:43

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...

Poseida Therapeutics Q4 EPS $(0.27) Beats ...
03/07/2024 21:38:14

Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of ...

Poseida Therapeutics Highlights Recent Pro...
01/04/2024 13:03:21

Reported positive early clinical data for allogeneic myeloma cell therapy P-BCMA-ALLO1 at ASH 2023 supporting potential of TSCM...

Piper Sandler Maintains Overweight on Pose...
12/11/2023 16:28:18

Piper Sandler analyst Edward Tenthoff maintains Poseida Therapeutics (NASDAQ:PSTX) with a Overweight and raises the price ta...

poseida-therapeutics-new-treatment-for-multiple-myeloma-shows-early-success-in-clinical-trial

Poseida Therapeutics' New Treatment For Mu...
12/11/2023 16:17:11

Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its ...

Market-Moving News for December 11th
12/11/2023 13:56:26

PSTX: 73% | Poseida Therapeutics Presented Early Results From Its Phase 1 Trial Of Allogeneic CAR-T P-BCMA-ALLO1 In Relapsed-Re...